Neuralink, Synchron, and the BCI Industry
A handful of well-funded companies are racing to bring brain-computer interfaces to humans — with very different bets on invasiveness, channel count, scale, and timeline.
Key facts
- Neuralink N1: 1,024 channels, fully wireless, robotically inserted.
- Synchron Stentrode: minimally invasive, FDA breakthrough designation.
- Precision Neuroscience: 1,024-channel surface microelectrode array, reversible.
- Paradromics Connexus: 1,600+ channels per implant.
- Onward demonstrated targeted spinal stimulation restoring walking in tetraplegic patients (2024).
Neuralink
High-bandwidth, fully implanted, robotically inserted flexible electrode threads (the N1 implant has 1,024 electrodes across 64 threads). First human implants began in early 2024 under FDA IDE; the PRIME trial restored cursor and game control to patients with quadriplegia.
Neuralink is pursuing speech, vision (Blindsight), and motor restoration in parallel programs.
Synchron
Endovascular Stentrode is delivered through the jugular vein into the superior sagittal sinus, avoiding open-brain surgery and enabling a faster regulatory and commercial pathway with lower bandwidth.
Synchron holds FDA breakthrough designation and has implanted patients in both the US (COMMAND) and Australia.
Other Players
Paradromics (Connexus, 1,600+ channels), Precision Neuroscience (surface microelectrode arrays, 1,024+ channels, reversible), Blackrock Neurotech (Utah array veterans, Neuralace next-gen), Onward (spinal-cord stimulation for paralysis), Inbrain Neuroelectronics (graphene electrodes), and Science Corp (Max More, retinal and BCI work).
Chinese players (NeuraMatrix, StairMed) are scaling rapidly under different regulatory regimes.
How They Differ
Invasiveness vs bandwidth is the central trade-off. Stentrodes are easier to deploy but cap out at lower channel counts; intracortical arrays read single units but require craniotomy.
Business models also diverge: medical-device first (Synchron, Precision, Onward) vs platform-first (Neuralink).
Frequently asked
When will BCIs be consumer products?
+
Not soon. Medical applications dominate the next decade; consumer use depends on safety, value, durability, and form-factor breakthroughs that are not on the near-term roadmap.
Is Neuralink ahead?
+
Ahead on channel count and ambition; behind some competitors on regulatory milestones and minimally invasive approaches. 'Ahead' depends on which axis.
What happens if a BCI company goes bankrupt?
+
A real ethical issue. Second Sight's bankruptcy left implanted patients without support. Industry, regulators, and ethicists are pushing for explant and continuity-of-care commitments.
Sources & further reading
Continue in this series
Foundations
Brain-Computer Interfaces: An Overview
Therapeutics
Neural Implants and Stimulation
Frontier
Memory Prosthetics and Cognitive Augmentation
Ethics
Neurorights and the Ethics of Reading the Brain
Outlook
The Future of Brain-Computer Interfaces